Purple Biotech Ltd. ADR
PPBT
Purple Biotech Ltd. ADR is a clinical-stage biotechnology company focused on developing first-in-class therapies for cancer. Its current pipeline centers on treatments designed to overcome tumor immune evasion and drug resistance, two major barriers that can limit the effectiveness of oncology care. The company’s programs include antibody-based immunotherapies and small-molecule candidates aimed at the tumor microenvironment, with research directed toward solid tumors and treatment-resistant cancers. Purple Biotech works at the intersection of immuno-oncology and precision drug development, seeking to address complex mechanisms that help cancer cells survive and evade treatment. Headquartered in Rehovot, Israel, Purple Biotech Ltd. ADR is positioned as a specialized cancer-focused developer within the broader biotechnology market.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$25M
▼ -264.0% YoY
Op. Margin
–
ROIC
-25.63%
▼ -0.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▲ +60.6% YoY
Op. Cash Flow (TTM)
-$8M
▲ +53.7% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$10M
Continue Research
Peers
Biotechnology · Pick stocks to compare with PPBT
Purple Biotech Ltd. ADR (PPBT) in three numbers
Questions about Purple Biotech Ltd. ADR
Is Purple Biotech Ltd. ADR a high-quality business?
Purple Biotech Ltd. ADR scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$9M, and its weakest is return on capital at -25.6%. The Quality tab shows every check against its target.
Does Purple Biotech Ltd. ADR (PPBT) pay a dividend?
No. Purple Biotech Ltd. ADR (PPBT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PPBT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.